Chembio Diagnostics, Inc. (CEMI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
6.14+0.48 (+8.48%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close5.66
Bid5.12 x 100
Ask0.00 x
Day's Range5.68 - 6.20
52wk Range3.51 - 9.40
1y Target EstN/A
Market Cap73.6M
P/E Ratio (ttm)-6.07
Avg Vol (3m)76,975
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    Chembio Expands Product Distribution through Exclusive Agreement with Isla Lab in the Caribbean

    MEDFORD, N.Y., Aug. 18, 2016-- Chembio Diagnostics, Inc., a leader in point-of-care diagnostic tests for infectious diseases, today announced that the Company has entered into an exclusive distribution ...

  • Zacks Small Cap Research9 days ago

    CEMI: Significant Growth Opportunity in Fever Accelerating Shift From STD

    In late July Chembio preannounced expected Q2 revenue of $3.2M - $3.3M.  Lower U.S. lateral flow sales and DPP sales to FIOCRUZ were cited as the reasons for the implied ~50% contraction from both the prior year period as well as from Q1 of this was  year.  Following the preannouncement we downwardly revised our $5.0M estimate to $3.3M, including $2.6M in product sales (from $4.2M) and $677k from license, R&D contracts and grants income (from $810k). Last week Chembio reported financial results for the second quarter ending June 30th.  While grant income was well ahead of our number ($1.2M A vs. $677k E) due to greater and earlier than anticipated recognition of a bulk of the Paul G. Allen fever panel grant, product sales came in about 21% shy ($2.0M A vs. $2.6m E) of our revised estimate.  The difference in actual and our revised product sales number is mostly concentrated in lower international lateral flow - which is not a particular concern given the great historical variability in this line item and the relationship to (hard to predict) international aid tenders.

  • Chembio Diagnostics, Inc. :CEMI-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016
    Capital Cube13 days ago

    Chembio Diagnostics, Inc. :CEMI-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016

    Categories: Yahoo Finance Click here to see latest analysis Chembio Diagnostics, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Chembio Diagnostics, Inc. – Quidel Corporation, Trinity Biotech Plc Sponsored ADR Class A, Bio-Rad Laboratories, Inc. Class A and Vermillion, Inc. (QDEL-US, TRIB-US, BIO-US and VRML-US) ... Read more (Read more...)